Related Experiment Videos
Pharmaceutical aspects of docetaxel
1Investigational Drug Section, Institute for Drug Development, San Antonio, TX 78229, USA.
Summary
This review covers docetaxel clinical trials and pharmacokinetics. Docetaxel is effective for advanced breast cancer, with a recommended dose of 100 mg/m2 and a 47% response rate in anthracycline-resistant cases.
Area of Science:
- Oncology
- Pharmacology
- Clinical Pharmacy
Background:
- Docetaxel is a chemotherapy agent used for various cancers.
- Understanding its clinical trial data, pharmacokinetics, and pharmaceutical preparation is crucial for effective use.
Purpose of the Study:
- To review the clinical trials, pharmacokinetics, and pharmaceutical aspects of docetaxel.
- To provide guidance on dosage, administration, and preparation for healthcare professionals.
Main Methods:
- Review of Phase I and Phase II clinical trial data.
- Analysis of pharmacokinetic studies.
- Evaluation of pharmaceutical formulations and preparation guidelines.
Main Results:
- Maximum tolerated dose in Phase I trials: 80-115 mg/m2; dose-limiting toxicity: neutropenia.
- Recommended Phase II dose: 100 mg/m2 every three weeks.
- Docetaxel exhibits linear pharmacokinetics with a ~12-hour half-life.
- Overall response rate of 47% in anthracycline-resistant breast cancer.
- Hepatic dysfunction increases drug concentration and adverse effects.
- Commercial formulations require specific preparation to achieve a 10 mg/mL concentration.
Conclusions:
- Docetaxel is indicated for advanced or metastatic breast cancer resistant to anthracyclines.
- Careful attention to preparation and administration is necessary to avoid dosage errors.
- Docetaxel is suitable for outpatient administration.